Product Description
Pelubiprofen is an orally active, non-steroidal anti-inflammatory drug and a member of the 2-arylpropionic acid family, which has a relatively selective effect on the activity of COX-2. Pelubiprofen inhibits COX activity and the TGF-β -activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects.
AI Product Description
*The following content is generated by AI and is for reference only.
Pelubiprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivative class, structurally related to ibuprofen and naproxen. Its chemical identity is defined by the molecular formula C15H20O3 and it is registered under CAS number 69784-39-4. The compound features a chiral center, with the pharmacologically active enantiomer typically being the S-isomer, which exhibits potent inhibition of cyclooxygenase enzymes. By blocking these enzymes, pelubiprofen effectively reduces the synthesis of prostaglandins, the lipid compounds responsible for mediating pain, inflammation, and fever responses within the human body.
Clinically, pelubiprofen is primarily utilized for the symptomatic treatment of various inflammatory conditions. It is widely prescribed to manage musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Additionally, it serves as a therapeutic agent for acute soft tissue injuries, including sprains, strains, and tendonitis, providing significant relief from associated swelling and discomfort. The drug is also employed in dental surgery contexts to alleviate post-operative pain and edema. Due to its high potency, pelubiprofen often demonstrates efficacy at lower dosages compared to some other NSAIDs, potentially offering a favorable safety profile regarding gastrointestinal irritation when administered correctly. However, like all drugs in this class, it carries risks of adverse effects, including gastric ulcers, renal impairment, and cardiovascular events, necessitating careful patient screening and monitoring during long-term therapy.
The pharmaceutical industry produces pelubiprofen in various formulations, including immediate-release tablets, sustained-release capsules, and topical gels, allowing for flexible administration routes tailored to specific patient needs. While not as globally ubiquitous as ibuprofen, it remains a valuable option in several markets, particularly in East Asia, for managing chronic pain and acute inflammatory episodes. Ongoing research continues to explore its potential applications and comparative efficacy against newer COX-2 selective inhibitors, ensuring its place in modern analgesic therapeutics.
(All Rights Reserved)![6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one](https://eimg.pharmasources.com/image/20250617/4zoOybJjzUTk0UgguabMkX7VnrDIlxHluERwqkjK.jpg)
